Skip to main content
. Author manuscript; available in PMC: 2013 Aug 13.
Published in final edited form as: J Am Coll Cardiol. 2011 May 27;58(1):73–82. doi: 10.1016/j.jacc.2010.12.044

Figure 3. SS-31 ameliorates Ang-induced cardiac hypertrophy and diastolic dysfunction.

Figure 3

(A) Ang for 4 weeks substantially increased LV mass index in control mice. Simultaneous administration of SS-31 significantly attenuated this increase in LVMI (left panel). This was similar extent to that observed in mice with inducible overexpression of mitochondrial catalase (i-mCAT, right panel). (B) Fractional shortening (FS,%) was not significantly changed after 4 weeks of Ang in the presence or absence of mitochondrial antioxidants. (C) Diastolic function measured by tissue Doppler imaging of Ea/Aa was significantly reduced after Ang, but was significantly ameliorated by SS-31 or genetic overexpression of mCAT. Administration of NAC for 4 weeks did not confer any significant protection for Ang-induced hypertrophy and diastolic dysfunction (light blue bar on left panel, A–C). n=6–7